A2 BIOTHERAPEUTICS

Serial Number 97796895
731

Registration Progress

Application Filed
Feb 15, 2023
Under Examination
May 21, 2024
Approved for Publication
Mar 6, 2024
Published for Opposition
Mar 26, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 2 Granted
Due: Nov 21, 2025 126 days

Trademark Image

A2 BIOTHERAPEUTICS

Basic Information

Serial Number
97796895
Filing Date
February 15, 2023
Published for Opposition
March 26, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
731
Status Date
May 12, 2025
Application
Pending
Classes
005

Rights Holder

A2 Biotherapeutics, Inc.

03
Address
30301 Agoura Road, Suite 210
Agoura Hills, CA 91301

Ownership History

A2 Biotherapeutics, Inc.

Original Applicant
03
Agoura Hills, CA

A2 Biotherapeutics, Inc.

Owner at Publication
03
Agoura Hills, CA

Legal Representation

Attorney
Joi A. White

USPTO Deadlines

Next Deadline
126 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
November 21, 2025
Extension Available
Until May 21, 2025

Application History

23 events
Date Code Type Description Documents
May 13, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 12, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 12, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
May 12, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 11, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 11, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 12, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 12, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
May 21, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 26, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 26, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 6, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 6, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 16, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 16, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 16, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 16, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 17, 2023 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Nov 17, 2023 GPRA F PRIORITY ACTION E-MAILED Loading...
Nov 17, 2023 CPRA R PRIORITY ACTION WRITTEN Loading...
Nov 14, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 6, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 18, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOTHERAPEUTICS